Inmune Bio (INMB) Price & Analysis

Compare

865 Followers

INMB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.89 - $11.64

Previous CloseN/A

Volume114.20K

Average Volume (3M)2.33M

Market Cap

$57.42M

Enterprise Value$20.90M

Total Cash (Recent Filing)$33.37M

Total Debt (Recent Filing)$451.00K

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Oct 29, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.05

Shares Outstanding26,585,258

10 Day Avg. Volume703,824

30 Day Avg. Volume2,326,142

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.36

Enterprise Value/Revenue417.93

Enterprise Value/Gross Profit417.93

Enterprise Value/Ebitda-0.37

Forecast

1Y Price Target

$7.72

Price Target Upside278.43% Upside

Rating ConsensusHold

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Market OpportunitiesWith the potential for premium pricing, this could represent a $1B opportunity.

Regulatory AdvancementsThe FDA has indicated during a Type C meeting that the data from the study could support a filing.

Bears Say

Alzheimer's Study ChallengesThe Phase 2 MINDFuL study in Alzheimer's disease for XPro missed the primary endpoint for cognitive change, leading to a significant drop in INMB shares.

Financial ConcernsThe company may need additional resources or a partner to conduct a larger Phase 3 study, indicating financial and logistical challenges.

Inmune Bio News

INmune Bio CEO RJ Tesi retires, David Moss succeeds

The company announced the following management changes: RJ Tesi retires as CEO; David Moss appointed president and CEO...

21d ago

INMB

INmune Bio reports Q2 EPS ($1.05), consensus (38c)

As of June 30, the company had cash and cash equivalents of approximately $33.4M. Published first on TheFly...

21d ago

INMB

INmune Bio options imply 16.2% move in share price post-earnings

Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 2:1. Implied volatility suggests the...

21d ago

INMB

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Blaize Holdings Inc (BZAI)...

23d ago

NNE

ARLP

INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints

INmune Bio (INMB) reports that its Phase I/II trial of INKmune for men with metastatic castration-resistant prostate cancer...

24d ago

INMB

INmune Bio options imply 14.9% move in share price post-earnings

Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 10:7. Implied volatility suggests the...

28d ago

INMB

Inmune Bio’s Earnings Call: Progress Amid Challenges

Inmune Bio (($INMB)) has held its Q2 earnings call. Read on for the main highlights of the call....

16d ago

INMB

Inmune Bio: Strategic Position and Growth Potential Amid Leadership Change and Promising Pipeline

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio, with...

16d ago

INMB

INmune Bio Reports Q2 2025 Results and Strategic Updates

Inmune Bio ( ($INMB) ) has released its Q2 earnings. Here is a breakdown of the information Inmune...

21d ago

INMB

INmune Bio Completes Phase I/II Trial for INKmune™

The latest update is out from Inmune Bio ( ($INMB) ). On August 4, 2025, INmune Bio announced...

21d ago

INMB

INmune Bio Releases Video on Alzheimer’s Trial Results

Inmune Bio ( ($INMB) ) just unveiled an update. On July 29, 2025, INmune Bio announced the release...

30d ago

INMB

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Draganfly (DPRO) 127.43% +1.80,...

1M ago

ACB

CNK

INmune Bio announces video detailing findings from Phase 2 MINDFuL trial

INmune Bio (INMB) announced that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating...

1M ago

INMB

Inmune Bio Reveals Promising XPro™ Trial Results

An update from Inmune Bio ( ($INMB) ) is now available. On July 24, 2025, INmune Bio Inc....

1M ago

INMB

INMB FAQ

What was Inmune Bio Inc’s price range in the past 12 months?

Inmune Bio Inc lowest stock price was $1.89 and its highest was $11.64 in the past 12 months.

What is Inmune Bio Inc’s market cap?

Inmune Bio Inc’s market cap is $57.42M.

When is Inmune Bio Inc’s upcoming earnings report date?

Inmune Bio Inc’s upcoming earnings report date is Oct 29, 2025 which is in 62 days.

How were Inmune Bio Inc’s earnings last quarter?

Inmune Bio Inc released its earnings results on Aug 07, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.384 by -$0.666.

Is Inmune Bio Inc overvalued?

According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inmune Bio Inc pay dividends?

Inmune Bio Inc does not currently pay dividends.

What is Inmune Bio Inc’s EPS estimate?

Inmune Bio Inc’s EPS estimate is -0.33.

How many shares outstanding does Inmune Bio Inc have?

Inmune Bio Inc has 26,585,258 shares outstanding.

What happened to Inmune Bio Inc’s price movement after its last earnings report?

Inmune Bio Inc reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.384. Following the earnings report the stock price went down -8.244%.

Which hedge fund is a major shareholder of Inmune Bio Inc?

Currently, no hedge funds are holding shares in INMB

Inmune Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-168.34%

Trailing 12-Months

Asset Growth

-28.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inmune Bio Inc

Inmune Bio, Inc. (INMB) is a biotechnology company focused on developing innovative therapies to modulate components of the immune system to treat cancer and neurodegenerative diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary platforms to target innate immune cells. Core products in its pipeline include INKmune, which aims to enhance the ability of natural killer cells to attack cancer, and XPro1595, designed to inhibit neuroinflammation linked to Alzheimer's disease.

Inmune Bio (INMB) Earnings & Revenues

Historic Earnings Reports

INMB Company Deck

INMB Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted progress in clinical trials and strategic plans for therapeutic platforms, but faced challenges with unmet primary endpoints and financial losses. The company is exploring strategic partnerships and remains optimistic about future developments.View all INMB earnings summaries

INMB Stock 12 Month Forecast

Average Price Target

$7.72

▲(278.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","-1":"-$1","4.75":"$4.75","10.5":"$10.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.75,10.5,16.25,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.56,3.9784615384615387,5.396923076923077,6.815384615384616,8.233846153846155,9.652307692307694,11.070769230769232,12.48923076923077,13.90769230769231,15.326153846153849,16.744615384615386,18.163076923076925,19.58153846153846,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.56,2.956923076923077,3.353846153846154,3.750769230769231,4.147692307692308,4.544615384615385,4.941538461538462,5.338461538461539,5.735384615384616,6.132307692307693,6.52923076923077,6.926153846153847,7.323076923076924,{"y":7.72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.56,2.4092307692307693,2.2584615384615385,2.1076923076923078,1.956923076923077,1.8061538461538462,1.6553846153846155,1.5046153846153847,1.353846153846154,1.2030769230769232,1.0523076923076924,0.9015384615384616,0.7507692307692309,{"y":0.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >